Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...
BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...
RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...
TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...
The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...
Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it...
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...